Name: Biopharmaceutical process development – Trends/ Challenges/Opportunities
Start: 2020-08-19T04:30:00Z
End: 2020-08-19T05:33:00.000Z
Location: BrightTALK
Rating: 5

BioPharma Webinars aims to keep its 30,000 readers abreast of all developments in the areas of Drug Development, Drug Delivery, Manufacturing, Quality Assurance, Outsourcing and Regulatory Affairs, with only the highest quality articles, written by the most respected authors, associated with only end-user companies. This ensures that the information will always be guaranteed to remain timely, informative and above all totally unbiased.

The webinar will provide an insight into a global deployment program for an automated solution for Endotoxin testing. A range of implementation aspects will be covered in the webinar including the change management approach for a global platform technology, technical implementation challenges and how they were overcome and harmonization of business processes and best practices within a global company.

LESSONS & BENEFITS GAINED FROM THE IMPLEMENTATION OF AN AUTOMATED BET SOLUTION

Full Title: Orthogonal Measures of Lentiviral Particle Attributes Using DLS, NTA, and Micro Flow Cytometry 

Orthogonal Measures of Lentiviral Particle Attributes Using DLS, NTA, and Micro Flow Cytometry.  Lentiviral vectors are used in multiple cell and gene therapy programs, both ex vivo and in vivo.  During production, enveloped lentiviral particles are produced along with other membrane bound particles that may or may have similar proteins content and other properties.  Throughout the production, purification, formulation and storage of these products, monitoring the quantity, size distribution, charge, and protein content can be helpful.  There are many different instruments and methodologies that facilitate these analyses, such as Dynamic Light Scattering, Nanoparticle Tracking Analysis, Flow Virometry, and protein analysis by ELISA and Western Blot.  This talk will cover the utility of using these and other analytical methods to assist product developers who seek to implement robust processes that reproducibly produce high quality products.

Orthogonal Measures of LVP Using DLS, NTA, & Micro Flow Cytometry

This presentation will provide an understanding related to Global Guidance related to holistic Contamination Control Strategies.  The importance of cross-functional collaboration to ensure all aspects of the Contamination Control Strategies are properly applied and modified based upon appropriate feedback, including CAPA from deviations. This presentation will also discuss how to identify and drive innovation within the manufacturing space to improve Sterility Assurance processes and development of future facility and process design. Finally, this presentation will discuss how to manage regulatory interactions, which can lead to successful audits.

Harmonized Manufacturing Network For Sterility Assurance

Full title: Variability, Limits, and Other Considerations for the Next Generation of Pyrogen and Endotoxin Testing 

The Limulus Amebocyte Lysate (LAL) test has been the “gold standard” test for endotoxins since the 1980s.  In 2023, we find ourselves at an exciting crossroads.  We are thinking “outside of the box” with respect to using recombinant and cellular based technologies that promise to make improvements to the existing lysate-based methods.  But as technology evolves, should we also be evolving in our thinking regarding assay capability/variability?  Given the clear benefits of the LAL test in process control and the statistically irrelevant final sample size for drug product testing, should we consider parametric release?  How do we think about setting appropriate endotoxin limits for complex or combination drugs or drugs used in infusions?  Is 20EU/device an appropriate limit for all medical devices?  Given ongoing research into microorganism adaptation and microbiome, what is the appropriate role of the current purified E. coli calibration standard?

Can we be content with 2023 technologies that are mired in 1980s thinking?  This webinar describes the events and thinking that got us here and poses some food for thought moving forward.

Variability, Limits, and Other Considerations for the Next Generation...

Characterization of residual impurities for gene therapy drug products is particularly challenging due to the complex nature of the final products as well as the complicated processes required to manufacture them. As these products advance through clinical development, the identification, characterization, and control of the process- and product-related impurities are important to define early on, and require careful assessment of impurity clearance and risk related to each impurity. This talk will focus on risk assessment and characterization of product-related impurities in lentiviral vector-based gene therapy products.

Characterization of Residual Impurities in Gene Therapy Drug Products

Full title: Process Analytical Technologies – Advances in Bioprocess Integration to Transition to Digital Manufacturing

Process Analytical Technology (PAT) instruments include analyzers capable of measuring physical and chemical process parameters and key attributes with the goal of optimizing process controls. PAT probes and sensors are intended for understanding bioprocesses with a goal to control quality and consistency at all stages of product manufacturing to achieve quality-by-design (QbD) and real-time release. The advantages and challenges, and the future development will be discussed

Process Analytical Technologies – Advances in Bioprocess Integration...

Presented by Andrew Falconbridge Vice President Process Technology and Innovation, Alvotech

A Hybrid Approach to Continuous Biomanufacturing of Biosimilars

Leachable risk management continues to be of regulatory interest. However we continue to rely on experimental extractable studies as predictors of leachable risk. These are complex to design and implement, and do not always offer the answer to what is the leachable risk for a drug product or medical device. We hope to show that mass transport modelling provide an alternative or a complementary element to testing the leachable risk. There are relatively simple mathematical models which can be developed which might provide an estimate of maximum leaching in a system. These can estimate factors such as solubility, partitioning and diffusion if successfully constructed and in combination these can estimate leaching. There are several ways which these might be modelled and this presentation will discuss each one. The presentation will illustrate where modelling might replace or support current approaches which rely upon experimental study. Results from modelling is complementary to risk appraisal, as predictive modelling gives quick insight into effects of storage time, temperature and other kinetics of leaching. This could be used to screening different materials and predict their leaching characteristics perhaps more effectively and efficiently than current extractable test protocols leading to better leachables studies to confirm these models.

Mass Transport Modelling in support of leachable risk management.

Full title: The Importance of Accurate Chemical Characterization of Medical Devices Extractables

The Importance of Accurate Chemical Characterization of Medical Devices...

Full title: Utilizing Cell Culture Platform and High-Throughput Bioreactors to Streamline Upstream Process Development and manufacturing scale up 

Discuss how to accelerate the clone selection with using the bioreactor systems
Understand how to implement the bioreactor systems e­ffectively with a minimal resources    
Know how to scale-down model definitions suitable for design space, QbD, or other BLA-enabling activities.

Utilizing Cell Culture Platform and High-Throughput Bioreactors to Streamline...

Full Title: Commercial Cell Therapy Experience Using Mycoplasma NAT For Product Release: Five-Year Review

Commercial Cell Therapy Experience Using Mycoplasma NAT For Product Release...

Presented by Dr Clemens Günther, Senior Expert Nonclinical Safety, Director at Bayer AG, R&D Pharmaceuticals

Safety Evaluation on Extractables and Leachable

UNICAN: Dual capability in single use bioreactors

Disposable technology is being used more each year in the biotechnology industry. Disposable bioreactors allow one to avoid expenses associated with cleaning, assembly and operations, as well as equipment validation. However, one of the biggest challenges for single use technology including single use bioreactor is single sourcing of consumables. Typically, the consumables are tied to the hardware eliminating the flexibility and interchangeability among existing systems, which ultimately forces the end user to rely on a single vendor’s supply chain. In order to address to this challenge, a 200L bottom mounted single-use bioreactor was converted into a universal can, or “Unican”, which supports the use of both bottom mounted agitator and top mounted agitator single use bioreactors. The implementation of Unican increases flexibility for cell culture operations, improves assurance of supply, allows handling of any bag film changes/issues in future and reduces the dependence on single suppliers. As part of the project, mass transfer and cell culture experiments were performed to ensure optimal performance of both bags in the Unican. Cell Culture data and mass transfer was shown to be comparable in both top and bottom mounted bags with historical data. Additionally, the modification of system was performed such that no hardware requalification was required post modification. The system has been successfully implemented in pilot plant for bioprocessing.

UNICAN: Dual capability in single use bioreactors

Downstream protein purification and product concentration is known to be the most challenging part of the process development. It is also known that the Downstream process development is critical to ensure protein drug’s quality, safety & efficacy meet regulatory expectations. When initiating the development, the Chemistry, manufacturing and controls considerations for process development and manufacturing must include molecule complexity. Raw materials, process development. Equipment and manufacturing, Quality and Regulatory affairs. The critical factors for development and manufacturing is performing stage-wise assessment on Product development, analytical and process development and not the least, the manufacturability assessment. The expected qualities of a superlative process shall include increased capacity, flexibility, cost-effectiveness, controllability, scalability, and efficiency. However, general challenges exist in downstream process development involving,

Balancing higher cost chromatography resins and solvents
Constrained purification space for molecules prone to degradation at wide range of pH and temperature
Process fit to multi-product facility,
PAT availability to accelerated processing
Adaptation of new technologies one of smarter way to address the challenges:
Non-Protein A process
use of next-generation chromatography resins
Continuous processing for capture, intermediate purification, Viral clearance

Best Practices of Downstream Protein Purification and Product Concentration

Full Title: Annex 1 and Environmental Monitoring Program - Implementation And Justification of The Best Practices In Routine

What is new? How to implement the changes?
EM program and Contamination Control Strategy
Example of Risk Analysis Methodology
EM program and Data Management
 

Presented by Benoit Ramond, Head of Microbiology & Sterile Technology at Sanofi

Benoît Ramond is a Doctor in Pharmacy at the University of Paris XI in France and obtains a PhD in Microbiology. He has more than 30 years of experiences in the Pharmaceutical Industry. Since 2016 he is Head of Microbiology and Sterile Technology Expertise in Sanofi Group including Aseptic Processing, Barrier Technologies, Environmental Monitoring Program, Cleaning and Disinfection, Visual Inspection.  In his function he has also a leading role in the Annex 1 implementation program within Sanofi.

Annex 1 and Environmental Monitoring Program - Implementation And Justification.

Digitally Transforming Pharmaceutical Process Development and Manufacturing: Enabling Technologies for a Sustainable Future

The focus on accelerated development of new modalities for advanced therapies and challenges with complex drug candidates has driven adoption of novel concepts and technologies in pharmaceutical development and manufacturing. The active substances have become more structurally complex and R&D timelines continue to be compressed, the technologies necessary to provide safe, robust and economical access to these molecules needs to keep pace. Enabling technologies such as automation and associated information management systems are increasingly being used in the development and manufacturing of therapeutics across the pharmaceutical industry to collect, analyze, and interpret an immense amount of advantageous process data that would otherwise be inaccessible. This combination provides many additional benefits, such as enabling processes, ability to safely handle highly reactive, unstable, and toxic reagents. All these aspects help to minimize the time and cost associated with development and manufacture of drugs and bring medicines to patients more effectively. The importance of such concepts has become even more evident in recent Covid-19 pandemic crisis, different organizations are actively thinking of implementing these paradigms to their benefit. In order to fully leverage and integrate the larger organization, end-to-end automation and information management strategy and vision is necessary where there is seamless workflow for automated route screening to optimization and scale-up of robust process is established. This presentation will share AbbVie’s strategy and experiences in integrating such end-to-end technologies into process development and manufacturing facilities and discuss the challenges and opportunities associated with our approaches.

Digitally Transforming Pharmaceutical Process Development and Manufacturing

Presented by Dr. Markus Zeitz, Head of Global Quality Digital Transformation at Boehringer Ingleheim

Quality Analytics –How to Leverage Quality Data for QMS 2.0

Batch to Continuous Technology: The Journey from Laboratory to Pilot Scale for DS Manufacturing

The presentation outlines a case-study in establishing the operational space of a Grignard reaction in a series of continuous stirred tank reactors (CSTRs). The development of a laboratory scale continuous flow process for the manufacture of a key intermediate of the pharmaceutical product Ipatasertib for the treatment of metastatic castration-resistant prostate cancer and triple negative metastatic breast cancer involves flow and batch unit operations. In a head-to-head comparison between the continuous and batch processes, the former was clearly superior as it gave a higher yield (81% vs 63%) of the product and better reaction control for handling the unstable reaction intermediates. Short residence times, accurate temperature and pH control and steady concentration profiles enabled the synthesis of product in excellent and invariable purity The gathered data and experiences from this study was crucial for guiding the decision making process in order to design a suitable pilot setup for the subsequent cGMP campaign.

Batch to Continuous Technology: The Journey from Laboratory to Pilot Scale...

Presented by Kumar Gaurav, AGM (Regulatory Affairs) at Panacea Biotec Ltd

Current trends and regulation affecting Biopharmaceutical Industry
Journey from Lab scale to Commercial –Overcoming Scalability design hurdles
QbD-Bringing Improvements in Biologics development and Manufacturing Space

Followed by Quality by Design (QbD) Approach for a Virus Filtration Application
Presented by Sudhakar Nagaraj, Principal Scientist, SLS – Global Regulatory and  Validation Consulting group at Pall Biotech

Removal of viruses in bioprocessing applications is a fundamental regulatory requirement, and the use of virus filtration is considered a robust and well accepted component of a virus clearance strategy. With the advent of the International Conference of Harmonization (ICH) Q8 Pharmaceutical Development and Q9 Quality Risk Management guidelines, there is much greater emphasis for filter users to define the filter design space, in addition to performing the mandatory virus filtration validation studies.
A thorough understanding of the virus filtration design space not only alleviates the risk of viral contamination, but an in-depth understanding of the boundaries of the process parameters ensures the manufacturing process remains in control. In this webinar, we describe an approach to implement QbD principles into virus filtration to create a safe and robust biomanufacturing process.

Biopharmaceutical process development – Trends/ Challenges/Opportunities

Bioprocessing

The medical research community on BrightTALK brings together medical and research professionals. Find relevant webinars on medical research, laboratory science, continuing medical education and more presented by recognized medical researchers. Join the conversation by participating in live webinars and round table discussions on the latest in medical devices, medical research practices and trends in the healthcare industry.

Medical Research

Thousands of healthcare IT professionals compose the health IT community on BrightTALK. Learn alongside them with relevant webinars on healthcare IT compliance, big data in healthcare and IT solutions for healthcare organizations. Join the conversation by asking questions and engaging with other participants during live webinars and organized discussions.

Health IT

Join the BrightTALK forensic science community for access to online forensics training from respected professionals in the field. Study forensic science online to learn necessary skills for trace evidence in forensics, liquid and gas chromatography and sample preparation. You can also attend live webinars to interact with forensic scientists and have your questions answered.

Forensic Science

Get powerful life science insights from influential experts. Connect with thought leaders and colleagues to get the most up-to-date knowledge on strategies and initiatives to accelerate the transformation of U.S. and global health care from a volume- to value-based marketplace.

Life Sciences

The research and development community on BrightTALK brings together leading professionals in healthcare, technology and manufacturing to present on current topics in their fields. From big data in healthcare to online forensics training and medical research practices, the community is an exceptional resource for those looking to expand their knowledge. Be part of the conversation by joining the community and participating in interactive live webinars.

Biopharmaceutical process development – Trends/ Challenges/Opportunities

Presented by

About this talk

More from this channel